Trial Profile

A Phase IIa clinical trial of resveratrol (JNS-115) in patients with Parkinson's Disease

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 10 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

02 Mar 2026 According to Jupiter Neurosciences media release, the data from the trial will be presented at the Biotechnology Innovation Organization (BIO) Investment and Growth Summit 2026.
05 Nov 2025 According to Jupiter Neurosciences media release, the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application to initiate a Phase 2a clinical trial of JOTROL in patients with Parkinson's disease. Trial initiation expected in early 2026.
27 Oct 2025 According to Jupiter Neurosciences media release, company enters into agreements for up to $20 million in flexible financing. company intends to use the proceeds from these facilities primarily to support the Phase 2 trial of its lead asset to complete.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com